An alternative method for purifying and detoxifying diphtheria toxin

Toxicon

Volumn 57, Issue 7-8, 2011, Pages 1093-1100

  Fratelli, Fernando ^a   Abrahão Neto, José ^b   Prestia Caricati, Aline Tojeira ^a   Marques Borges, Monamaris ^a   Guidolin, Rosalvo ^a   Caricati, Celso Pereira ^a  

^a INSTITUTO BUTANTAN   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cytotoxicity; Detoxification; Diphtheria toxin; Pegylation

Indexed keywords

DIPHTHERIA TOXIN; DIPHTHERIA TOXOID; MACROGOL; METHOXYPOLYETHYLENE GLYCOL; NEUTRALIZING ANTIBODY; NITROGEN; SEPHAROSE; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ANTIGEN PURIFICATION; ARTICLE; CELL DEATH; CELL SWELLING; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG CONJUGATION; DRUG FORMULATION; DRUG PURIFICATION; GUINEA PIG; IMMUNOGENICITY; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; TOXIN ANALYSIS; VERO CELL;

BACTERIA (MICROORGANISMS); CAVIA; CORYNEBACTERIUM DIPHTHERIAE;

EID: 79956338135     PISSN: 00410101     EISSN: 18793150     Source Type: Journal    
DOI: 10.1016/j.toxicon.2011.04.015     Document Type: Article

References (34)

1. Aggerbeck H., Heron I. Detoxification of diphtheria and tetanus toxin with formaldehyde. Detection of protein conjugates. Biologicals 1992, 20(2):109-115.
2. Ahlstedt S., Björkander J., Akerblom E. Antibody responses to honey-bee venon and monomethoxy-polyethylene glycol modified honey-bee venon in mice. Int. Arch. Allergy Appl. Immunol. 1983, 71:228-232.
3. Antoni G., Bigio M., Borri G., Casagli M.C., Neri P. Purification of diphtheria toxin by chromatography on Cibacron blue Sepharose. Experientia 1983, 39(8):885-886.
4. Bennett M.J., Choe S., Eisemberg D. Refined structure of dimeric diphtheria toxin at 2.0 A resolution. Protein Sci. 1994, 3:1444-1463.
5. Bitoh S., Wakefield R., Lang G.M., Sehon A.H. Inhibition of the effector phase of IgE mediated allergies by tolerogenic conjugates of allergens and monomethoxypolyethylene glycol. Int. Arch. Allergy Immunol. 1995, 107:316-318.
6. Brooks G.F., Bennett J.V., Feldman R.A. Diphtheria in the United States, 1959-1970. J. Infect. Dis. 1974, 129:172-178.
7. Calicete P., Veronese F.M. Pharmacokinetic and biodistribution properties of poly(ethyleneglycol) protein conjugates. Adv. Drug Del. Rev. 2003, 55:1261-1277.
8. Caliceti P., Veronese F.M., Jonak Z. Immunogenic and tolerogenic properties ofmonomethoxypoly (ethylene glycol) conjugated proteins. Farmaco 1999, 54:430-437.
9. Celis E., Wiktor T.J., Dietzschold B., Koprowski H. Amplificacion of rabies virus-induced stimulation of human T-cell lines and clones by antigen-specific antibodies. J. Virol. 1985, 56:426-433.
10. Duncan R., Spreafico F. Polymer conjugates. Pharmacokinetic considerations for design and development. Clin. Pharmacokinet. 1994, 27:290-306.
11. Frech C., Hilbert A.K., Hartmann G., Mayer K., Sauer T., Bolgiano B. Physicochemical analysis of purified diphtheria toxoids: is toxoided then purified the same as purified then toxoided?. Dev. Biol. 2000, 103:205-215.
12. Funke G., von Graevenitz A., Clarridge J.E., Bernard K.A. Clinical microbiology of coryneform bacteria. Clin. Microbiol. Rev. 1997, 10:125-159.
13. Gill D.M. Bacterial toxin. A table of lethal amount. Microbial. Rev. 1982, 46:86-94.
14. Katre N.V. Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol. J. Immunol. 1990, 144:209-213.
15. Kumar S., Kanwar S., Bansal V., Sehgal R. Standardization and validation of Vero cell assay for potency estimation of diphtheria antitoxin serum. Biologicals 2009, 37(5):297-305.
16. 4. Nature 1970, 227(5259):680-685.
17. Long D.A. Immune and allergic reactions to diphtheria toxin and toxoid in guinea-Pigs. J. Hyg. 1959, 57(2):216-226.
18. Mekada E., Okada Y., Uchida T. Identification of diphtheria toxin receptor and a nonproteinous diphtheria toxin-biding molecule in Vero cell membrane. J. Clin. Biol. 1988, 107:511-519.
19. Metza B., Jiskoot W., Hennink E.W., Daan J.A., Crommelin D.J.A., Gideon F.A.K. Physicochemical and immunochemical techniques predict the quality of diphtheria toxoid vaccines. Vaccine 2003, 22:156-167.
20. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
21. Murphy B.R., Walsh E.E. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibition activity. J. Clin. Microbiol. 1988, 26:1595-1597.
22. Nencioni L., Volpini G., Peppoloni S., Bugnoli M., De Magistris T., Marsili I., Rappuoli R. Properties of pertussis toxin mutant PT-9K/129G after formaldehyde treatment. Infect. Immun. 1991, 59:625-630.
23. Nordvall S.L., Uhlin T., Ohman S., Björkander J., Malling H.J., Weeke B., Dreborg S., Lanner A., Einarsson R. IgG and IgE antibody patterns after immunotherapy with monomethoxy polyethyleneglycol modified honey bee venom. Allergy 1986, 41:89-94.
24. Openhshaw P.J.M., Culley F.J., Olszewska W. Immunophatogenesis of vaccine-enhanced RSV disease. Vaccine 2001, 20:27-31.
25. Paliwal R., London E. Comparison of the conformation, hydrophobicity, and model membrane interactions of diphtheria toxin to those of formaldehyde-treated toxin (diphtheria toxoid): formaldehyde stabilization of the native conformation inhibits changes that allow membrane insertion. Biochemistry 1996, 35:2374-2379.
26. Pappenheimer A.M. Diphtheria toxin. Annu. Rev. Biochem. 1977, 46:69-94.
27. Pasut G., Veronese F.M. PEGylation for improving the effectiveness of therapeutic biomolecules. Drugs Today 2009, 45(9):687-695.
28. Rambelli F., Brigotti M., Sperti S., Montanaro L. Interaction of diphtheria toxin fragment A and of elongation factor 2 with Cibacron blue. Biosci. Rep. 1987, 7:737-743.
29. Rappuoli R. Toxin inactivation and antigen stabilization: two different uses of formaldehyde. Vaccine 1994, 12:579-581.
30. So T., Ito H., Tsujihata Y., Hirata M., Ueda T., Imoto T. The molecular weightratio ofmonomethoxypolyethylene glycol (mPEG) to protein determines the immunotolerogenicity of mPEG proteins. Protein Eng. 1999, 12:701-705.
31. De Swat R.L. Immunization of macaques with formalin-inactivated respiratory synctial virus (RSV) induces interleukine-13 associated hypersensitivity to subsequent RSV infection. J. Virol. 2002, 76:11561-11569.
32. World Health Organization Working Group on revision of the Manual of Laboratory Methods for Testing DTP Vaccines. Report of two meetings held on 20-21 July 2006 and 28-30 March 2007, Geneva, Switzerland. Vaccine 2008, 26:1913-1921. WHO.
33. Working P.K., Newman M.S., Johnson J. Safety of poly (Ethylene Glycol) and poly (Ethylene Glycol) derivatives. Poly (Ethylene Glycol): Chemistry and Biological Applications 1997, 45-59. American Chemical Society, San Franciso, CA. J.M. Harris, S. Zaplinsky (Eds.).
34. Yang Z., Wang J., Lu Q., Xu J., Kobayashi Y., Takakura T., Takimoto A., Yoshioka T., Lian C., Chen C., Zhang D., Shang Y., Li S., Sun X., Tan Y., Yagi S., Frenkel E.P., Hoffman R.M. Pegylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates. Cancer Res. 2004, 64:6673-6678.